A Marine still serves despite Cancer
A battle with Hodgkins Lymphoma didn't stop this man from serving his country"
"If late stage cancer can’t stop Petty Officer 3rd Class Chris Zunker, then the U.S. Navy’s Basic Underwater Demolition/Seal training program might want to watch out.
Zunker, a corpsman who is preparing to depart the 2nd Marine Logistics Group, returned from a successful tour in Iraq last April where he served with a Marine Corps military transition team –a deployment that almost never happened.
After being diagnosed with Hotchkins Lymphoma in April 2006 at the age of 22, it looked like Zunker’s time in the Navy had come to an abrupt end, and his time serving with the Corps would never occur.
Zunker awoke one morning with a sore neck and a few days later had a lump the size of his fist where the pain had started. He had the late stage cancer on much of his head, neck and chest."
Read More: http://www.marines.mil/unit/2ndmlg/Pages/Cancersurvivor.aspx
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
